- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
310
(CaN), which promotes apoptosis, occurs in two rodent models of glaucoma (induced rat model and DBA/2J mice), but not after optic nerve crush (Huang et al., 2005). Finally, heterozygosity for a Bax null allele protects RGC somas from apoptosis after a glaucomatous insult that causes axonal degeneration, but not after crush (Libby et al., 2005b).
Recently, Yang and colleagues performed a microarray analysis between RGC death induced by optic nerve transection and pressure-induced neurodegeneration (translimbal laser photocoagulation) (Yang et al., 2007). By comparing gene expression changes following crush and during experimental glaucoma and then filtering out genes that changed in both models, they report gene expression changes that are suggested to be specific to pressure-induced injury (Yang et al., 2007).
Mouse models to characterize processes involved in glaucomatous neurodegeneration
The death of RGCs and the associated degeneration of the optic nerve are unifying features of glaucoma, but the underlying mechanisms are poorly understood. In recent years, the DBA/2J strain has become the most widely used inherited mouse model to study glaucomatous neurodegeneration. In this section, we describe how the DBA/2J model (and the related strain, DBA/2NNia, collectively referred to as DBA/2) is being used to understand mechanisms involved in neurodegeneration during glaucoma.
Similar patterns of glaucomatous damage occur in humans and mice
A characteristic feature of human glaucoma is the occurrence of focal visual defects due to regionspecific loss or impairment of RGCs. The most consistent regional defects are arcuate scotomas, which are detected by visual field tests (Shields, 1997). The arcuate nerve fibers originate in the temporal region of the retina and arch above or below the fovea to the optic nerve head. In the mouse, the RGC axons do not curve across the retinal surface but radiate straight toward the optic nerve. Considering this, patterns of regional
damage equivalent to that in human patients occur in mice. In DBA/2 mice, RGCs and their axons are lost in ‘‘fan-shaped’’ or ‘‘patchy’’ regions (Danias et al., 2003; Jakobs et al., 2005; Schlamp et al., 2006). These fan-shaped regions of RGC loss are likely to be analogous to the arcuate scotomas seen in human glaucoma. This regional pattern of RGC loss during glaucoma is likely to result from focal damage to discrete’’bundles’’ of axons within the lamina.
The lamina cribrosa is an important site of early glaucomatous damage
Important studies in humans and primates established that early glaucomatous damage affects the RGC axon segments within the lamina cribrosa (Anderson and Hendrickson, 1974, 1977; Quigley and Anderson, 1977; Quigley et al., 1979, 1980, 1981, 1983; Quigley and Addicks, 1980, 1981). In humans and primates, the lamina cribrosa is composed of plates of extracellular matrix (ECM) that provide support for the axons as they pass through the posterior wall of the eye (Fig. 2a). It was hypothesized that in response to elevated IOP, bowing of the ECM plates would damage axon bundles by mechanical stress. Mechanical distortion of the ECM plates has also been suggested to contribute to glaucoma by damaging blood vessels (Quigley and Addicks, 1981; Maumenee, 1983; Fechtner and Weinreb, 1994). The ECM plates are covered by astrocytes that provide neurotrophic and other forms of support to the neurons.
Historically, the mouse was not regarded as a useful model for glaucoma because it was reported to lack a lamina cribrosa (Tansley, 1956; Fujita et al., 2000; Morcos and Chan-Ling, 2000; May and Lutjen-Drecoll, 2002). However, the mouse does have an astrocyte-rich structure in the same position as the human lamina cribrosa (Xie et al., 2005; Petros et al., 2006; Schlamp et al., 2006; Howell et al., 2007). The astrocytes of this region form an enmeshing network of glial cells through which the RGC axons pass, and they are intimately associated with the axons. There is no evidence of collagenous ECM plates in this region of the mouse optic nerve. To reflect the equivalent location compared to the human lamina cribrosa,
311
Fig. 2. (A–C) The lamina cribrosa has robust ECM plates (A, shown in blue, Masson’s Trichrome) through which bundles of axons pass. In contrast, the mouse glial lamina has no collagenous plates (B), although collagens are clearly visible in blood vessel walls (arrowheads). Similar to the human lamina, the mouse glial lamina has an extensive meshwork of astrocytes (C, stained positive for GFAP). (D–F) Early focal damage at the glial lamina is visualized using DBA/2J.Thy1-CFP mice. In these mice, RGC axons appear green when viewed by confocal microscopy. Because axonal contents accumulate in regions of damage, early axon damage is evident as very brightly fluorescent axon segments (arrows). (D) No damage is seen in preglaucomatous young eyes. (E) Obvious axonal swellings were evident specifically in the lamina of eyes that were at early stages of glaucoma. (F) Focal regions of damage are clearly visible as bright, slightly swollen axonal regions (arrowheads). Scale bars: (A) 1 mm; (B, C) 50 mm; (D–F) 20 mm. (A) Adapted with permission from Karim et al. (2004). (B–F) Adapted with permission from Howell et al. (2007). (See Color Plate 22.2 in color plate section.)
the similar arrangement of glial cells, but the absence of ECM plates, this region of the mouse optic nerve has been termed the glial lamina (Howell et al., 2007).
An insult occurs to the axons of RGCs within the lamina in glaucoma
The mechanisms by which RGC somata die are different from those involved in axon degeneration. This was shown by genetically ablating the function of BAX, a proapoptotic molecule, in DBA/2J mice. BAX deficiency prevented the death of essentially all RGC soma, but the axons of these mice were still degenerated (Libby et al., 2005b). Therefore, in these mice at least, RGC soma death is a BAX-dependent apoptotic process, whereas axon degeneration is a BAX-independent process.
Similar to studies in other species (see above), we determined that the first sign of axon damage occurs within the lamina in DBA/2J mice (Fig. 2) (Howell et al., 2007). Demonstrating that the first
signs of axon damage occur within the lamina is not proof that axons are insulted within the lamina. In the general case, it is well established that the first site of neuronal damage may be remote from the site of insult (reviewed in Conforti et al., 2007). For example, in transected motor axons, neuromuscular junctions that are many centimeters from the lesion degenerate first. The axons immediately adjacent to the lesion remain intact for two to three times longer than the distant terminals (Beirowski et al., 2005). We have demonstrated that RGC axons survive up to, but not into, the lamina in BAX-deficient mice that retain all of their RGC soma. This provides strong experimental evidence supporting a direct insult to RGC axons within the lamina during glaucoma (Guo et al., 2007; Howell et al., 2007). Given that DBA/2J mice develop glaucoma with regional cell death and characteristic optic nerve excavation, the lack of ECM plates in the lamina suggests mechanical distortion of ECM plates is not necessary to damage axons within the lamina
312
during glaucoma. Although it remains possible that the ECM plates may modulate damage in human glaucoma (as the nerve is much larger), these findings strongly focus attention on other components of the lamina.
What is the nature of the insult at the lamina?
One current challenge is to identify mechanism(s) initiating axon damage at the lamina and not just the processes involved in the propagation of axon degeneration. This is of particular importance when considering improved human therapies. It is possible that the initiating events are either intrinsic to the RGC itself or extrinsic involving other cell types. Other important cell types that are present in the optic nerve are glial cells (such as astrocytes, microglia, and oligodendrocytes). These cell types ordinarily play important roles in maintaining healthy, fully functioning RGCs, but in response to stressful conditions can become harmful. Examples of pathways/molecules known to be active in these different cell types during glaucomatous injury are given below to highlight the possible importance of all of these cell types in glaucomatous neurodegeneration.
Intrinsic changes in RGCs leading to axon degeneration in glaucoma are reported. An interesting line of research relates to amyloid precursor protein (APP) and amyloid-b (Ab). Mutations in APP cause Alzheimer’s disease (AD), and recent studies imply that there is a significantly higher incidence of glaucoma among patients with AD (Bayer et al., 2002). The same abnormal Ab peptide found in AD was found in AqH of 40% of the assessed glaucoma patients. In addition, in a rat model of glaucoma, caspase-3, a major activator of the apoptotic cascade, is activated in RGCs and cleaves APP to produce neurotoxic fragments that include Ab (McKinnon et al., 2002; McKinnon, 2003). Supporting this, Goldblum and colleagues have shown that APP and Ab increase in the RGC layer, lamina, and pia/dura layer in aged DBA/2 mice (15 months old) compared to young DBA/2J and C57BL/6J controls (Goldblum et al., 2007). They suggest a disruption of the homeostatic properties of secreted APP with consecutive Ab cytotoxicity as a contributing
factor to RGC loss in glaucoma. This would suggest that glaucoma and AD share common features, and suggests mechanisms identified as important in one disease should be investigated in the other. A promising study suggests that targeting different components of Ab formation and aggregation pathway can effectively reduce glaucomatous RGC apoptosis as shown in an experimental glaucoma in rats (Guo et al., 2007).
Astrocytes form a cellular network in the glial lamina in the mouse. It has been suggested that IOP elevation can alter astrocytes so that they damage RGC axons (Hernandez, 2000). Astrocytes become reactive in glaucoma. An increase in glial fibrillary acidic protein (GFAP) is considered a hallmark of reactive astrocytes (Pekny and Nilsson, 2005). GFAP is upregulated in experimental models of glaucoma in primates and rats (Tanihara et al., 1997; Wang et al., 2000), as well as in human glaucomatous eyes (Tezel et al., 2003). Two independent microarray experiments, the first in an experimentally induced rat model, the second using DBA/2J mice, showed increases in the expression of astro- cyte-related genes in response to elevated IOP (Ahmed et al., 2004; Steele et al., 2006), and we have made similar observations (unpublished data).
Microglia are another cell type present in the optic nerve and may contribute to glaucoma (Tezel and Wax, 2004; May and Mittag, 2006; Nakazawa et al., 2006). Microglia increase in numbers as glaucoma progresses, and this is true in DBA/2J mice (Inman and Horner, 2007). It is possible that microglia are necessary to initiate or propagate damage in the retina or optic nerve. Individual microglia may contribute to highly local insults within specific regions of the lamina and could conceivably underlie the fan-shaped patterns of cell death.
Oligodendrocytes were recently suggested to participate in glaucoma (Nakazawa et al., 2006). Oligodendrocytes are numerous in the optic nerve from the start of the myelinated portion (approximately 100 mm behind the glial lamina in mice). Axons within the glial lamina are unmyelinated and no myelin-producing oligodendrocytes have been shown to be present within the glial lamina. Based on findings using an induced model of high IOP, an intriguing model involving TNFa and oligodendrocyte death was suggested to damage RGCs in
